Enveric Biosciences Reports $2.5 Million Q3 Loss, $5.6 Million in Cash

Enveric Biosciences reported a net loss attributable to stockholders of $2.5 million, or $0.57 per share, for the third quarter of 2026. The company had $5.6 million in cash as of September 30, 2026. It also reported progress on EB-003’s IND-enabling work as it prepares for a planned IND submission…